

Commission Regulation (EU) 2019/831 of 22 May 2019 amending Annexes II, III and V to Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products (Text with EEA relevance)

COMMISSION REGULATION (EU) 2019/831

of 22 May 2019

amending Annexes II, III and V to Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products⁽¹⁾, and in particular Article 15(1), the fourth subparagraph of Article 15(2) and Article 31(1) thereof,

Whereas:

- (1) Regulation (EC) No 1272/2008 of the European Parliament and of the Council⁽²⁾ provides for a harmonised classification of substances as carcinogenic, mutagenic or toxic for reproduction (CMR) based on a scientific assessment by the Risk Assessment Committee of the European Chemicals Agency. The substances are classified as CMR substances of category 1A, CMR substances of category 1B or CMR substances of category 2 depending on the level of evidence of their CMR properties.
- (2) Article 15 of Regulation (EC) No 1223/2009 provides that substances which have been classified as CMR substances of category 1A, category 1B or category 2 under Part 3 of Annex VI to Regulation (EC) No 1272/2008 (CMR substances) are prohibited from use in cosmetic products. A CMR substance may however be used in cosmetic products where the conditions laid down in the second sentence of Article 15(1) or in the second subparagraph of Article 15(2) of Regulation (EC) No 1223/2009 are fulfilled. This Regulation implements Regulation (EC) No 1223/2009. Only the Court of Justice of the European Union is entitled to interpret Union law, including Article 15 of Regulation (EC) No 1223/2009.
- (3) In order to uniformly implement the prohibition of CMR substances within the internal market, to ensure legal certainty, in particular for economic operators and national competent authorities and to ensure a high level of protection of human health, all CMR substances should be included in the list of prohibited substances in Annex II to Regulation (EC) No 1223/2009 and, where relevant, deleted from the lists of restricted or authorised substances in Annexes III and V to that Regulation. Where the conditions laid down in the second sentence of Article 15(1) or the second subparagraph of Article 15(2) of Regulation (EC) No 1223/2009 are fulfilled, the lists of restricted or authorised substances in Annexes III and V to that Regulation should be amended accordingly.

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

- (4) This Regulation covers the substances which have been classified as CMR substances pursuant to Regulation (EC) No 1272/2008 as at 1 December 2018, when Commission Regulation (EU) 2017/776⁽³⁾ became applicable.
- (5) Concerning certain CMR substances for which a request for use in cosmetic products by way of exception has been submitted, it has not been established that all the conditions provided for in the second sentence of Article 15(1) or the second subparagraph of Article 15(2) of Regulation (EC) No 1223/2009 are fulfilled. This concerns Quaternium-15, Chloroacetamide, Dichloromethane, Formaldehyde, Perboric acid and Sodium perborate compounds
- (6) The substance Methenamine 3-chloroallylochloride, with the International Nomenclature of Cosmetic Ingredients (INCI) name Quaternium-15, is currently listed in entry 31 of Annex V to Regulation (EC) No 1223/2009 as allowed in a concentration of up to 0,2 % in ready for use preparation. Quaternium-15 is a mixture of cis and trans isomers of which the cis-isomer has been classified as a CMR substance of category 2 by Commission Regulation (EC) No 790/2009⁽⁴⁾. The classification became applicable on 1 December 2010. In accordance with the second sentence of Article 15(1) of Regulation (EC) No 1223/2009, a substance classified in category 2 may be used in cosmetic products where the substance has been evaluated by the Scientific Committee on Consumer Safety (SCCS) and found safe for use in cosmetic products. On 13 and 14 December 2011, the SCCS issued a scientific opinion on Quaternium-15 (cis-isomer)⁽⁵⁾, which concluded that on the basis of the available data the safety of Quaternium-15 for use in cosmetic products cannot be established. In light of the classification of the cis-isomer present in Quaternium-15 as a CMR substance of category 2 and the opinion of the SCCS, Quaternium-15 should be deleted from the list of preservatives allowed in cosmetic products in Annex V to Regulation (EC) No 1223/2009 and added to the list of substances prohibited in cosmetic products in Annex II to that Regulation.
- (7) The substance 2-Chloroacetamide, with the INCI name Chloroacetamide, is currently listed in entry 41 of Annex V to Regulation (EC) No 1223/2009 as allowed in a concentration of up to 0,3 % in ready for use preparation. Chloroacetamide has been classified as a CMR substance of category 2 under Regulation (EC) No 1272/2008. The classification became applicable before 1 December 2010, at which date Titles II, III and IV of Regulation (EC) No 1272/2008 became applicable in respect of substances. In accordance with the second sentence of Article 15(1) of Regulation (EC) No 1223/2009, a substance classified in category 2 may be used in cosmetic products where the substance has been evaluated by the SCCS and found safe for use in such products. On 22 March 2011, the SCCS issued a scientific opinion on Chloroacetamide⁽⁶⁾ which concluded that, on the basis of the available data, the substance is not safe for consumers when used in a concentration of up to 0,3 % w/w in cosmetic products. In light of the classification as a CMR substance of category 2 and the opinion of the SCCS, Chloroacetamide should be deleted from the list of preservatives allowed in cosmetic products in Annex V to Regulation (EC) No 1223/2009 and added to the list of substances prohibited in cosmetic products in Annex II to that Regulation.

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

- (8) The substance Dichloromethane is currently listed in entry 7 of Annex III to Regulation (EC) No 1223/2009 as allowed in cosmetic products in a concentration of up to 35 % in ready for use preparation. Dichloromethane has been classified as a CMR substance of category 2 under Regulation (EC) No 1272/2008. The classification became applicable before 1 December 2010. In accordance with the second sentence of Article 15(1) of Regulation (EC) No 1223/2009, a substance classified in category 2 may be used in cosmetic products where the substance has been evaluated by the SCCS and found safe for use in such products. On 11 December 2012, the SCCS issued a scientific opinion on Dichloromethane⁽⁷⁾. On 25 March 2015, the SCCS issued a new opinion⁽⁸⁾ which was revised on 28 October 2015. In that revised opinion the SCCS concluded that the use of Dichloromethane in a concentration of up to 35 % in hair sprays and its use in spray formulations in general is not considered safe for the consumer. In light of the classification as a CMR substance of category 2 and the opinion of the SCCS, and since no other uses of Dichloromethane in cosmetic products are known and have been covered by the SCCS opinion, the substance should be deleted from the list of restricted substances in Annex III to Regulation (EC) No 1223/2009 and added to the list of substances prohibited in cosmetic products in Annex II to that Regulation.
- (9) The substance Formaldehyde is currently listed in entry 13 of Annex III to Regulation (EC) No 1223/2009 as allowed in nail hardening products in a concentration of up to 5 % in ready for use preparation. It is also currently listed in entry 5 of Annex V to Regulation (EC) No 1223/2009 as allowed in oral products in a concentration of up to 0,1 % and in other products in a concentration of up to 0,2 %. Formaldehyde has been classified as a CMR substance of category 1B by Commission Regulation (EU) No 605/2014⁽⁹⁾. The classification became applicable on 1 January 2016. In accordance with the second subparagraph of Article 15(2) of Regulation (EC) No 1223/2009, substances classified as CMR substances of category 1A or 1B may be used in cosmetic products by way of exception where, subsequent to their classification as CMR substances, certain conditions are fulfilled, including the conditions that no suitable alternative substances are available, that an application is made for a particular use of the product category with a known exposure and that the substance has been evaluated and found safe by the SCCS. On 7 November 2014, the SCCS concluded in its opinion⁽¹⁰⁾ that ‘nail hardeners with a maximum concentration of about 2,2 % free formaldehyde can be used safely to harden or strengthen nails’. However, since it has not been established that there are no suitable alternative substances available for the purpose of hardening nails, Formaldehyde should be deleted from the list of restricted substances in Annex III to Regulation (EC) No 1223/2009. Since no application was made for other uses of Formaldehyde, the substance should be deleted from the list of preservatives allowed in cosmetic products in Annex V to that Regulation. Formaldehyde should also be added to the list of substances prohibited in cosmetic products in Annex II to Regulation (EC) No 1223/2009.
- (10) Perboric acid and Sodium perborate compounds are covered by the hydrogen peroxide releasing substances currently listed in entry 12 of Annex III to Regulation (EC) No 1223/2009. They have been classified as CMR substances of category 1B by Regulation (EC) No 790/2009. The classification became applicable by 1 December 2010. A

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

request for the application of the second subparagraph of Article 15(2) of Regulation (EC) No 1223/2009 was submitted for the use of those substances in oxidative hair dye formulations. On 22 June 2010, the SCCS concluded in its opinion⁽¹¹⁾ that the ‘general restrictions applicable to hydrogen peroxide releasing substances should apply to sodium perborate and perboric acid and that the use of sodium perborates as an ingredient in oxidative hair dye formulations with a maximum on-head concentration of 3 % will not pose a risk to the health of the consumer’. However, since it has not been established that there are no suitable alternative substances available for the purpose of oxidation of hair, Perboric acid and Sodium perborate compounds should be deleted from the list of restricted substances in Annex III to Regulation (EC) No 1223/2009 and added to the list of substances prohibited in cosmetic products in Annex II to that Regulation.

- (11) Concerning certain substances which were classified as CMR substances under Regulation (EC) No 1272/2008 and for which a request for the application of the second sentence of Article 15(1) of Regulation (EC) No 1223/2009 has been submitted, it has been established that the condition provided for in that provision is fulfilled. This concerns Trimethylbenzoyl diphenylphosphine oxide, Furfural and Polyaminopropyl biguanide.
- (12) The substance Diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide, with the INCI name Trimethylbenzoyl diphenylphosphine oxide (TPO), is currently not included in the Annexes to Regulation (EC) No 1223/2009. TPO has been classified as a CMR substance of category 2 by Commission Regulation (EU) No 618/2012⁽¹²⁾. The classification became applicable on 1 December 2013. On 27 March 2014, the SCCS issued a scientific opinion⁽¹³⁾ which concluded that TPO is safe when used as a nail modelling product in a concentration of up to 5,0 % but that it is however a moderate skin sensitizer. Considering the skin sensitising properties of TPO and the high risk of exposure through skin contact in case of self-application of nail products, the use of TPO should be restricted to professionals only. In light of those elements, TPO should be added to the list of restricted substances in Annex III to Regulation (EC) No 1223/2009 for professional use in artificial nail systems with a maximum concentration of 5 %.
- (13) The substance 2-Furaldehyde, with the INCI name Furfural, is used as a fragrance or flavour ingredient in cosmetic products and is currently not included in the Annexes to Regulation (EC) No 1223/2009. It has been classified as a CMR substance of category 2 under Regulation (EC) No 1272/2008. The classification became applicable before 1 December 2010. On 27 March 2012, the SCCS concluded in its opinion⁽¹⁴⁾ that the use of Furfural in a concentration of up to 10 ppm (0,001 %) in ready for use preparation, including oral products, does not pose any risk to the health of the consumer. In light of the classification of Furfural as a CMR substance of category 2 and the opinion of the SCCS, Furfural should be added to the list of restricted substances in Annex III to Regulation (EC) No 1223/2009 with a maximum concentration of 0,001 %.
- (14) The substance Polyhexamethylene biguanide hydrochloride (PHMB), with the INCI name Polyaminopropyl Biguanide, is currently listed as a preservative in entry 28 of Annex V to Regulation (EC) No 1223/2009 with a maximum concentration of 0,3 %.

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

It has been classified as a CMR substance of category 2 by Commission Regulation (EU) No 944/2013⁽¹⁵⁾. The classification became applicable on 1 January 2015. On 18 June 2014, the SCCS adopted an opinion⁽¹⁶⁾ which concluded that on the basis of the data available, PHMB is not safe for consumers when used as a preservative in all cosmetic products at a maximum concentration of 0,3 %. However, the SCCS opinion also concluded that the safe use could be based on a lower use concentration and/or restrictions with regard to cosmetic products' categories and that dermal absorption studies on additional representative cosmetic formulations are needed. On 7 April 2017, the SCCS adopted a new opinion⁽¹⁷⁾ which concluded that, based on the data provided, the use of PHMB as a preservative in all cosmetic products up to 0,1 % is safe but that its use in sprayable formulations is not advised. In light of the classification of PHMB as a CMR substance of category 2 and of the new SCCS opinion, PHMB should be authorised as a preservative in all cosmetic products, except in applications that may lead to exposure of the end-user's lungs by inhalation, with a maximum concentration of 0,1 %. The conditions set out in Annex V to Regulation (EC) No 1223/2009 should be adapted accordingly.

- (15) Concerning a large group of substances which were classified as CMR substances under Regulation (EC) No 1272/2008, no request for use in cosmetic products by way of exception has been submitted. Those substances should be included in the list of prohibited substances in Annex II to Regulation (EC) No 1223/2009 and, where relevant, deleted from the lists of restricted or authorised substances in Annexes III and V to that Regulation. This concerns, inter alia, some boron compounds currently listed in entries 1a and 1b of Annex III to Regulation (EC) No 1223/2009.
- (16) Some boron compounds currently listed in entries 1a and 1b of Annex III to Regulation (EC) No 1223/2009 and Dibutyltin hydrogen borate have been classified as CMR substances of category 1B by Regulation (EC) No 790/2009. The classification became applicable by 1 December 2010. In accordance with the second subparagraph of Article 15(2) of Regulation (EC) No 1223/2009, substances classified as CMR substances of category 1A or 1B may be used in cosmetic products by way of exception where, subsequent to their classification as CMR substances, certain conditions are fulfilled. On 22 June 2010, the SCCS issued an opinion⁽¹⁸⁾ which concluded that some of the boron compounds currently listed in entries 1a and 1b of Annex III to that Regulation are safe for use in cosmetics under certain conditions. However, since no application for a particular use was made and since it has not been established that there are no suitable alternative substances available for the purpose of the relevant uses listed in Annex III to Regulation (EC) No 1223/2009, those boron compounds should be deleted from the list of restricted substances in Annex III to that Regulation and added to the list of substances prohibited in cosmetic products in Annex II to Regulation (EC) No 1223/2009. As regards Dibutyltin hydrogen borate, no application for a particular use was made and it has not been found safe by the SCCS. That substance should therefore be added to the list of substances prohibited in cosmetic products in Annex II to Regulation (EC) No 1223/2009.
- (17) Article 31(1) of Regulation (EC) No 1223/2009 provides that where there is a potential risk to human health, arising from the use of substances in cosmetic products,

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

which needs to be addressed on a Community-wide basis, the Commission may, after consulting the SCCS, amend Annexes II to VI to that Regulation accordingly. The Commission has consulted the SCCS on the safety of certain substances which are similar from a chemical perspective to substances classified as CMR substances of categories 1A, 1B or 2. This concerns certain boron compounds as well as Paraformaldehyde and Methylene Glycol.

- (18) Certain boron compounds currently listed in entries 1a and 1b of Annex III to Regulation (EC) No 1223/2009, other than those referred to in Recital 16, have not been classified as CMR substances. On 12 December 2013, the SCCS issued an opinion on borates, tetraborates and octaborates⁽¹⁹⁾, where it concluded that those substances, as well as other boric acid salts or esters, such as MEA-borate, MIPA-borate, potassium borate, trioctyldecyl borate and zinc borate, form boric acid in aqueous solutions and that therefore the general restrictions applicable to boric acid should apply to the whole group of borates, tetraborates and octaborates. Boric acid has been classified as a CMR substance of category 1B by Regulation (EC) No 790/2009. The classification became applicable by 1 December 2010. In light of the opinion of the SCCS, the whole group of borates, tetraborates and octaborates, except the substances in that group that have been classified as CMR substances, as well as other boric acid salts or esters, should be deleted from the list of restricted substances in Annex III to Regulation (EC) No 1223/2009 and added to the list of substances prohibited in cosmetic products in Annex II to that Regulation.
- (19) The substance Paraformaldehyde is currently listed in entry 5 of Annex V to Regulation (EC) No 1223/2009 but, contrary to Formaldehyde, it has not been classified as a CMR substance. The substance Methylene Glycol is currently not included in the Annexes to Regulation (EC) No 1223/2009. On 26–27 June 2012, the SCCS adopted an opinion on Methylene Glycol⁽²⁰⁾ which established that Methylene Glycol is rapidly reversible under a variety of conditions to form Formaldehyde in aqueous solutions and that Paraformaldehyde can depolymerise to form Formaldehyde by heating or drying. In light of the opinion of the SCCS, there is a potential risk to human health arising from the use of those substances in cosmetic products. Paraformaldehyde should therefore be deleted from the list of preservatives allowed in cosmetic products in Annex V to Regulation (EC) No 1223/2009 and Paraformaldehyde and Methylene Glycol should be added to the list of substances prohibited in cosmetic products in Annex II to that Regulation.
- (20) Regulation (EC) No 1223/2009 should therefore be amended accordingly.
- (21) The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Cosmetic Products,

HAS ADOPTED THIS REGULATION:

Article 1

Annexes II, III and V to Regulation (EC) No 1223/2009 are amended in accordance with the Annex to this Regulation.

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the *Official Journal of the European Union*.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 22 May 2019.

For the Commission

The President

Jean-Claude JUNCKER

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

ANNEX

(1) Annex II is amended as follows:

(a) the following entries are added:

Reference number	Substance identification		
	Chemical name/ INN	CAS number	EC number
a	b	c	d
'1385	Cis-1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride (cis-CTAC)	51229-78-8	426-020-3
1386	Cis-1-(3-chlorallyl)-3,5,7-triaza-1-azoniaadamantane chloride (cis-CTAC), quaternium-15	51229-78-8	426-020-3
1387	2-Chloracetamide	79-07-2	201-174-2
1388	Octamethylcyclotetrasiloxane	5516-67-2	209-136-7
1389	Dichloromethane; methylene chloride	75-09-2	200-838-9
1390	2,2'-((3,3',5,5'-Tetramethyl-(1,1'-biphenyl)-4,4'-diyl)-bis(oxymethylene))-bis-oxirane	85954-11-6	413-900-7
1391	Acetaldehyde; ethanal	75-07-0	200-836-8
1392	1-Cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid	93107-30-3	413-760-7
1393	N-Methyl-2-pyrrolidone; 1-methyl-2-pyrrolidone	872-50-4	212-828-1
1394	Diboron trioxide; boric oxide	1303-86-2	215-125-8

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

1395	Boric acid [1] Boric acid [2]	10043-35-3 [1] 11113-50-1 [2]	233-139-2 [1] 234-343-4 [2]
1396	Borates, tetraborates, octaborates and boric acid salts and esters, including:		
	Disodium octaborate tetrahydrate [1]	12280-03-4 [1]	234-541-0 [1]
	2-Aminoethanol, monoester with boric acid [2]	10377-81-8 [2]	233-829-3 [2]
	2-Hydroxypropyl ammonium dihydrogen orthoborate [3]	68003-13-4 [3]	268-109-8 [3]
	Potassium borate, boric acid potassium salt [4]	12712-38-8 [4]	603-184-6 [4]
	Trioctyldodecyl borate [5]	[5]	— [5]
	Zinc borate [6]	1332-07-6 [6]	215-566-6 [6]
	Sodium borate, disodium tetraborate anhydrous; boric acid, sodium salt [7]	1330-43-4 [7]	215-540-4 [7]
	Tetraboron disodium heptaoxide, hydrate [8]	12267-73-1 [8]	235-541-3 [8]
	Orthoboric acid, sodium salt [9]	13840-56-7 [9]	237-560-2 [9]
	Disodium tetraborate decahydrate; borax decahydrate [10]	1303-96-4 [10]	215-540-4 [10]
Disodium tetraborate pentahydrate; borax pentahydrate [11]	12179-04-3 [11]	215-540-4 [11]	
1397	Sodium perborate [1]	15120-21-5 [1]	239-172-9 [1]

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

	Sodium peroxometaborate; sodium peroxoborate [2]	7632-04-4 [2] 10332-33-9 [2] 10486-00-7[2]	231-556-4 [2]
1398	Perboric acid (H ₃ BO ₂ (O ₂)), monosodium salt trihydrate [1]	13517-20-9 [1]	239-172-9 [1]
	Perboric acid, sodium salt, tetrahydrate [2]	37244-98-7 [2]	234-390-0 [2]
	Perboric acid (HBO(O ₂)), sodium salt, tetrahydrate sodium peroxoborate hexahydrate [3]	10486-00-7 [3]	231-556-4 [3]
1399	Perboric acid, sodium salt [1]	11138-47-9 [1]	234-390-0 [1]
	Perboric acid, sodium salt, monohydrate [2]	12040-72-1 [2]	234-390-0 [2]
	Perboric acid (HBO(O ₂)), sodium salt, monohydrate [3]	10332-33-9 [3]	231-556-4 [3]
1400	Dibutyltin hydrogen borate	75113-37-0	401-040-5
1401	Nickel bis(tetrafluoroborate)	14708-14-6	238-753-4
1402	Mancozeb (ISO); manganese ethylenebis(dithiocarbamate) (polymeric) complex with zinc salt	8018-01-7	616-995-5
1403	Maneb (ISO); manganese ethylenebis(dithiocarbamate) (polymeric)	12427-38-2	235-654-8
1404	Benfuracarb (ISO); ethyl N-[2,3-dihydro-2,2-dimethylbenzofuran-7-yl]oxycarbonyl(methyl)aminothio]-N-	82560-54-1	617-356-3

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

	isopropyl- β -alaninate		
1405	<i>O</i> -Isobutyl- <i>N</i> -ethoxy carbonylthiocarbamate	103122-66-3	434-350-4
1406	Chlorpropham (ISO); isopropyl 3-chlorocarbanilate	101-21-3	202-925-7
1407	<i>O</i> -Hexyl- <i>N</i> -ethoxycarbonylthiocarbamate	109202-58-6	432-750-3
1408	Hydroxylammonium nitrate	13465-08-2	236-691-2
1409	(4-Ethoxyphenyl) (3-(4-fluoro-3-phenoxyphenyl)propyl)dimethylsilane	105024-66-6	405-020-7
1410	Phoxim (ISO); α -(diethoxyphosphinothioylimino) phenylacetonitrile	14816-18-3	238-887-3
1411	Glufosinate ammonium (ISO); ammonium 2-amino-4-(hydroxymethylphosphinyl)butyrate	77182-82-2	278-636-5
1412	Reaction mass of: dimethyl (2-(hydroxymethylcarbamoyl)ethyl)phosphonate; diethyl (2-(hydroxymethylcarbamoyl)ethyl)phosphonate; methyl ethyl (2-(hydroxymethylcarbamoyl)ethyl)phosphonate	—	435-960-3
1413	(4-Phenylbutyl)phosphinic acid	86552-32-1	420-450-5
1414	Reaction mass of: 4,7-bis(mercaptomethyl)-3,6,9-trithia-1,11-undecanedithiol; 4,8-bis(mercaptomethyl)-3,6,9-trithia-1,11-undecanedithiol; 5,7-bis(mercaptomethyl)-3,6,9-trithia-1,11-undecanedithiol	170016-25-8	427-050-1

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

1415	Potassium titanium oxide (K ₂ Ti ₆ O ₁₃)	12056-51-8	432-240-0
1416	Cobalt di(acetate)	71-48-7	200-755-8
1417	Cobalt dinitrate	10141-05-6	233-402-1
1418	Cobalt carbonate	513-79-1	208-169-4
1419	Nickel dichloride	7718-54-9	231-743-0
1420	Nickel dinitrate [1]	13138-45-9 [1]	236-068-5 [1]
	Nitric acid, nickel salt [2]	14216-75-2 [2]	238-076-4 [2]
1421	Nickel matte	69012-50-6	273-749-6
1422	Slimes and sludges, copper electrolytic refining, decopperised, nickel sulfate	92129-57-2	295-859-3
1423	Slimes and sludges, copper electrolyte refining, decopperised	94551-87-8	305-433-1
1424	Nickel diperchlorate; perchloric acid, nickel(II) salt	13637-71-3	237-124-1
1425	Nickel dipotassium bis(sulfate) [1]	13842-46-1 [1]	237-563-9 [1]
	Diammonium nickel bis(sulfate) [2]	15699-18-0 [2]	239-793-2 [2]
1426	Nickel bis(sulfamidate); nickel sulfamate	13770-89-3	237-396-1
1427	Nickel bis(tetrafluoroborate)	14708-14-6	238-753-4
1428	Nickel diformate [1]	3349-06-2 [1]	222-101-0 [1]
	Formic acid, nickel salt [2]	15843-02-4 [2]	239-946-6 [2]
	Formic acid, copper nickel salt [3]	68134-59-8 [3]	268-755-0 [3]

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

1429	Nickel di(acetate) [1]	373-02-4 [1]	206-761-7 [1]
	Nickel acetate [2]	14998-37-9 [2]	239-086-1 [2]
1430	Nickel dibenzoate	553-71-9	209-046-8
1431	Nickel bis(4-cyclohexylbutyrate)	3906-55-6	223-463-2
1432	Nickel(II) stearate; nickel(II) octadecanoate	2223-95-2	218-744-1
1433	Nickel dilactate	16039-61-5	—
1434	Nickel(II) octanoate	4995-91-9	225-656-7
1435	Nickel difluoride [1]	10028-18-9 [1]	233-071-3 [1]
	Nickel dibromide [2]	13462-88-9 [2]	236-665-0 [2]
	Nickel diiodide [3]	13462-90-3 [3]	236-666-6 [3]
	Nickel potassium fluoride [4]	11132-10-8 [4]	— [4]
1436	Nickel hexafluorosilicate	26043-11-8	247-430-7
1437	Nickel selenate	15060-62-5	239-125-2
1438	Nickel hydrogen phosphate [1]	14332-34-4 [1]	238-278-2 [1]
	Nickel bis(dihydrogen phosphate) [2]	18718-11-1 [2]	242-522-3 [2]
	Trinickel bis(orthophosphate) [3]	10381-36-9 [3]	233-844-5 [3]
	Dinickel diphosphate [4]	14448-18-1 [4]	238-426-6 [4]
	Nickel bis(phosphinate) [5]	14507-36-9 [5]	238-511-8 [5]
	Nickel phosphinate [6]	36026-88-7 [6]	252-840-4 [6]
	Phosphoric acid, calcium nickel salt [7]	17169-61-8 [7]	— [7]

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

	Diphosphoric acid, nickel(II) salt [8]	19372-20-4 [8]	— [8]
1439	Diammonium nickel hexacyanoferrate	74195-78-1	—
1440	Nickel dicyanide	557-19-7	209-160-8
1441	Nickel chromate	14721-18-7	238-766-5
1442	Nickel(II) silicate [1]	21784-78-1 [1]	244-578-4 [1]
	Dinickel orthosilicate [2]	13775-54-7 [2]	237-411-1 [2]
	Nickel silicate (3:4) [3]	31748-25-1 [3]	250-788-7 [3]
	Silicic acid, nickel salt [4]	37321-15-6 [4]	253-461-7 [4]
	Trihydrogen hydroxybis[orthosilicato(4-)]trinickelate(3-) [5]	12519-85-6 [5]	235-688-3 [5]
1443	Dinickel hexacyanoferrate	14874-78-3	238-946-3
1444	Trinickel bis(arsenate); nickel(II) arsenate	13477-70-8	236-771-7
1445	Nickel oxalate [1]	547-67-1 [1]	208-933-7 [1]
	Oxalic acid, nickel salt [2]	20543-06-0 [2]	243-867-2 [2]
1446	Nickel telluride	12142-88-0	235-260-6
1447	Trinickel tetrasulfide	12137-12-1	—
1448	Trinickel bis(arsenite)	74646-29-0	—
1449	Cobalt nickel gray periclase; C.I. Pigment Black 25; C.I. 77332 [1]	68186-89-0 [1]	269-051-6 [1]
	Cobalt nickel dioxide [2]	58591-45-0 [2]	261-346-8 [2]
	Cobalt nickel oxide [3]	12737-30-3 [3]	620-395-9 [3]
1450	Nickel tin trioxide; nickel stannate	12035-38-0	234-824-9

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

1451	Nickel triuranium decaoxide	15780-33-3	239-876-6
1452	Nickel dithiocyanate	13689-92-4	237-205-1
1453	Nickel dichromate	15586-38-6	239-646-5
1454	Nickel(II) selenite	10101-96-9	233-263-7
1455	Nickel selenide	1314-05-2	215-216-2
1456	Silicic acid, lead nickel salt	68130-19-8	—
1457	Nickel diarsenide [1]	12068-61-0 [1]	235-103-1 [1]
	Nickel arsenide [2]	27016-75-7 [2]	248-169-1 [2]
1458	Nickel barium titanium primrose priderite; C.I. Pigment Yellow 157; C.I. 77900	68610-24-2	271-853-6
1459	Nickel dichlorate [1]	67952-43-6 [1]	267-897-0 [1]
	Nickel dibromate [2]	14550-87-9 [2]	238-596-1 [2]
	Ethyl hydrogen sulfate, nickel(II) salt [3]	71720-48-4 [3]	275-897-7 [3]
1460	Nickel(II) trifluoroacetate [1]	16083-14-0 [1]	240-235-8 [1]
	Nickel(II) propionate [2]	3349-08-4 [2]	222-102-6 [2]
	Nickel bis(benzenesulfonate) [3]	39819-65-3 [3]	254-642-3 [3]
	Nickel(II) hydrogen citrate [4]	18721-51-2 [4]	242-533-3 [4]
	Citric acid, ammonium nickel salt [5]	18283-82-4 [5]	242-161-1 [5]
	Citric acid, nickel salt [6]	22605-92-1 [6]	245-119-0 [6]
	Nickel bis(2-ethylhexanoate) [7]	4454-16-4 [7]	224-699-9 [7]

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

2-Ethylhexanoic acid, nickel salt [8]	7580-31-6 [8]	231-480-1 [8]
Dimethylhexanoic acid, nickel salt [9]	93983-68-7 [9]	301-323-2 [9]
Nickel(II) isooctanoate [10]	29317-63-3 [10]	249-555-2 [10]
Nickel isooctanoate [11]	27637-46-3 [11]	248-585-3 [11]
Nickel bis(isononanoate) [12]	84852-37-9 [12]	284-349-6 [12]
Nickel(II) neononanoate [13]	93920-10-6 [13]	300-094-6 [13]
Nickel(II) isodecanoate [14]	85508-43-6 [14]	287-468-1 [14]
Nickel(II) neodecanoate [15]	85508-44-7 [15]	287-469-7 [15]
Neodecanoic acid, nickel salt [16]	51818-56-5 [16]	257-447-1 [16]
Nickel(II) neoundecanoate [17]	93920-09-3 [17]	300-093-0 [17]
Bis(d.-gluconato- O^1, O^2)nickel [18]	71957-07-8 [18]	276-205-6 [18]
Nickel 3,5-bis(tert-butyl)-4-hydroxybenzoate (1:2) [19]	52625-25-9 [19]	258-051-1 [19]
Nickel(II) palmitate [20]	13654-40-5 [20]	237-138-8 [20]
(2-Ethylhexanoato- O)(isononanoato- O)nickel [21]	85508-45-8 [21]	287-470-2 [21]
(Isononanoato- O)(isooctanoato- O)nickel [22]	85508-46-9 [22]	287-471-8 [22]
(Isooctanoato- O)(neodecanoato- O)nickel [23]	84852-35-7 [23]	284-347-5 [23]
(2-Ethylhexanoato- O)	84852-39-1 [24]	284-351-7 [24]

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

	(isodecanoato- <i>O</i>)nickel [24]		
	(2-Ethylhexanoato- <i>O</i>) (neodecanoato- <i>O</i>)nickel [25]	85135-77-9 [25]	285-698-7 [25]
	(Isodecanoato- <i>O</i>) (isooctanoato- <i>O</i>)nickel [26]	85166-19-4 [26]	285-909-2 [26]
	(Isodecanoato- <i>O</i>) (isononanoato- <i>O</i>)nickel [27]	84852-36-8 [27]	284-348-0 [27]
	(Isononanoato- <i>O</i>) (neodecanoato- <i>O</i>)nickel [28]	85551-28-6 [28]	287-592-6 [28]
	Fatty acids, C ₆₋₁₉ - branched, nickel salts [29]	91697-41-5 [29]	294-302-1 [29]
	Fatty acids, C ₈₁₈ and C ₁₈ - unsaturated, nickel salts [30]	84776-45-4 [30]	283-972-0 [30]
	2,7- Naphthalenedisulfonic acid, nickel(II) salt [31]	72319-19-8 [31]	[31]
1461	Nickel(II) sulfite [1]	7757-95-1 [1]	231-827-7 [1]
	Nickel tellurium trioxide [2]	15851-52-2 [2]	239-967-0 [2]
	Nickel tellurium tetraoxide [3]	15852-21-8 [3]	239-974-9 [3]
	Molybdenum nickel hydroxide oxide phosphate [4]	68130-36-9 [4]	268-585-7 [4]
1462	Nickel boride (NiB) [1]	12007-00-0 [1]	234-493-0 [1]
	Dinickel boride [2]	12007-01-1 [2]	234-494-6 [2]
	Trinickel boride [3]	12007-02-2 [3]	234-495-1 [3]
	Nickel boride [4]	12619-90-8 [4]	235-723-2 [4]
	Dinickel silicide [5]	12059-14-2 [5]	235-033-1 [5]

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

	Nickel disilicide [6]	12201-89-7 [6]	235-379-3 [6]
	Dinickel phosphide [7]	12035-64-2 [7]	234-828-0 [7]
	Nickel boron phosphide [8]	65229-23-4 [8]	— [8]
1463	Dialuminium nickel tetraoxide [1]	12004-35-2 [1]	234-454-8 [1]
	Nickel titanium trioxide [2]	12035-39-1 [2]	234-825-4 [2]
	Nickel titanium oxide [3]	12653-76-8 [3]	235-752-0 [3]
	Nickel divanadium hexaoxide [4]	52502-12-2 [4]	257-970-5 [4]
	Cobalt dimolybdenum nickel octaoxide [5]	68016-03-5 [5]	268-169-5 [5]
	Nickel zirconium trioxide [6]	70692-93-2 [6]	274-755-1 [6]
	Molybdenum nickel tetraoxide [7]	14177-55-0 [7]	238-034-5 [7]
	Nickel tungsten tetraoxide [8]	14177-51-6 [8]	238-032-4 [8]
	Olivine, nickel green [9]	68515-84-4 [9]	271-112-7 [9]
	Lithium nickel dioxide [10]	12031-65-1 [10]	620-400-4 [10]
	Molybdenum nickel oxide [11]	12673-58-4 [11]	— [11]
1464	Cobalt lithium nickel oxide	—	442-750-5
1465	Molybdenum trioxide	1313-27-5	215-204-7
1466	Dibutyltin dichloride; (DBTC)	683-18-1	211-670-0
1467	4,4'-Bis(N-carbamoyl-4-methylbenzenesulfonamide)diphenylmethane	151882-81-4	418-770-5
1468	Furfuryl alcohol	98-00-0	202-626-1

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

1469	1,2-Epoxy-4-epoxyethylcyclohexane; 4-vinylcyclohexene diepoxide	106-87-6	203-437-7
1470	6-Glycidylloxynapht-1-yl oxymethyloxirane	27610-48-6	429-960-2
1471	2-(2-Aminoethylamino)ethanol; (AEEA)	111-41-1	203-867-5
1472	1,2-Diethoxyethane	629-14-1	211-076-1
1473	2,3-Epoxypropyltrimethylammonium chloride; glycidyl trimethylammonium chloride	3033-77-0	221-221-0
1474	1-(2-Amino-5-chlorophenyl)-2,2,2-trifluoro-1,1-ethanediol, hydrochloride	214353-17-0	433-580-2
1475	(E)-3-[1-[4-[2-(Dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol	82413-20-5	428-010-4
1476	4,4'-(1,3-Phenylene-bis(1-methylethylidene))bis-phenol	13595-25-0	428-970-4
1477	2-Chloro-6-fluorophenol	2040-90-6	433-890-8
1478	2-Methyl-5-tert-butylthiophenol	—	444-970-7
1479	2-Butyryl-3-hydroxy-5-thiocyclohexan-3-yl-cyclohex-2-en-1-one	94723-86-1	425-150-8
1480	Profoxydim (ISO); 2-{{(E)-1-[(2RS)-2-(4-chlorophenoxy)propoxyimino]butyl}-3-hydroxy-5-(thian-3-	139001-49-3	604-105-8

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

	yl)cyclohex-2-en-1-one		
1481	Tepraloxydim (ISO); (RS)-(EZ)-2-{1-[(2E)-3-chloroallyloxyimino]propyl}-3-hydroxy-5-perhydropyran-4-ylcyclohex-2-en-1-one	149979-41-9	604-715-4
1482	Cyclic 3-(1,2-ethanediylacetale)-estra-5(10),9(11)-diene-3,17-dione	5571-36-8	427-230-8
1483	Androsta-1,4,9(11)-triene-3,17-dione	15375-21-0	433-560-3
1484	Reaction mass of: Ca salicylates (branched C ₁₀₋₁₄ and C ₁₈₋₃₀ alkylated); Ca phenates (branched C ₁₀₋₁₄ and C ₁₈₋₃₀ alkylated); Ca sulfurised phenates (branched C ₁₀₋₁₄ and C ₁₈₋₃₀ alkylated)	—	415-930-6
1485	1,2-Benzenedicarboxylic acid; di-C ₆₈ -branched alkylesters, C ₇ -rich	71888-89-6	276-158-1
1486	Reaction mass of: diester of 4,4'-methylenebis[2-(2-hydroxy-5-methylbenzyl)-3,6-dimethylphenol] and 6-diazo-5,6-dihydro-5-oxonaphthalene-1-sulfonic acid (1:2); triester of 4,4'-methylenebis[2-(2-hydroxy-5-methylbenzyl)-3,6-dimethylphenol] and 6-diazo-5,6-	—	427-140-9

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

	dihydro-5-oxonaphthalene-1-sulfonic acid (1:3)		
1487	Diammonium 1-hydroxy-2-(4-(4-carboxyphenylazo)-2,5-dimethoxyphenylazo)-7-amino-3-naphthalenesulfonate	150202-11-2	422-670-7
1488	3-Oxoandrost-4-ene-17- β -carboxylic acid	302-97-6	414-990-0
1489	(Z)-2-Methoxyimino-2-[2-(tritylamino)thiazol-4-yl]acetic acid	64485-90-1	431-520-1
1490	Trisodium nitrilotriacetate	5064-31-3	225-768-6
1491	2-Ethylhexyl-2-ethylhexanoate	7425-14-1	231-057-1
1492	Diisobutyl phthalate	84-69-5	201-553-2
1493	Perfluorooctane sulfonic acid; heptadecafluorooctane-1-sulfonic acid [1]	1763-23-1 [1]	217-179-8 [1]
	Potassium perfluorooctanesulfonate; potassium heptadecafluorooctane-1-sulfonate [2]	2795-39-3 [2]	220-527-1 [2]
	Diethanolamine perfluorooctane sulfonate [3]	70225-14-8 [3]	274-460-8 [3]
	Ammonium perfluorooctane sulfonate; ammonium heptadecafluorooctanesulfonate [4]	29081-56-9 [4]	249-415-0 [4]
	Lithium perfluorooctane sulfonate; lithium heptadecafluorooctanesulfonate [5]	29457-72-5 [5]	249-644-6 [5]

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

1494	Ethyl 1-(2,4-dichlorophenyl)5-(trichloromethyl)-1 <i>H</i> -1,2,4-triazole-3-carboxylate	103112-35-2	401-290-5
1495	1-Bromo-2-methylpropyl propionate	158894-67-8	422-900-6
1496	Chloro-1-ethylcyclohexyl carbonate	99464-83-2	444-950-8
1497	6,6'-Bis(diazo-5,5',6,6'-tetrahydro-5,5'-dioxo)[methylene-bis(5-(6-diazo-5,6-dihydro-5-oxo-1-naphthylsulphonyloxy)-6-methyl-2-phenylene)]di(naphthalene-1-sulfonate)	—	441-550-5
1498	Trifluralin (ISO); α,α,α -trifluoro-2,6-dinitro- <i>N,N</i> -dipropyl- <i>p</i> -toluidine; 2,6-dinitro- <i>N,N</i> -dipropyl-4-trifluoromethylaniline; <i>N,N</i> -dipropyl-2,6-dinitro-4-trifluoromethylaniline	1582-09-8	216-428-8
1499	4-Mesyl-2-nitrotoluene	1671-49-4	430-550-0
1500	Triammonium 4-[4-[7-(4-carboxylatoanilino)-1-hydroxy-3-sulfonato-2-naphthylazo]-2,5-dimethoxyphenylazo]benzoate	221354-37-6	432-270-4
1501	Reaction mass of: triammonium 6-amino-3-((2,5-diethoxy-4-(3-phosphonophenyl)azo)phenyl)azo-4-hydroxy-2-naphthalenesulfonate; diammonium 3-	163879-69-4	438-310-7

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

	((4-((7-amino-1-hydroxy-3-sulfonaphthalen-2-yl)azo)-2,5-diethoxyphenyl)azo)benzoate		
1502	<i>N,N'</i> -Diacetylbenzidine	613-35-4	210-338-2
1503	Cyclohexylamine	108-91-8	203-629-0
1504	Piperazine	110-85-0	203-808-3
1505	Hydroxylamine	7803-49-8	232-259-2
1506	Hydroxylammonium chloride; hydroxylamine hydrochloride [1]	5470-11-1 [1]	226-798-2 [1]
	Bis(hydroxylammonium) sulfate; hydroxylamine sulfate (2:1) [2]	10039-54-0 [2]	233-118-8 [2]
1507	Methyl-phenylene diamine; diaminotoluene	—	—
1508	Mepanipyrim; 4-methyl- <i>N</i> -phenyl-6-(1-propynyl)-2-pyrimidinamine	110235-47-7	600-951-7
1509	Hydroxylammonium hydrogensulfate; hydroxylamine sulfate(1:1) [1]	10046-00-1 [1]	233-154-4 [1]
	Hydroxylamine phosphate [2]	20845-01-6 [2]	244-077-0 [2]
	Hydroxylamine dihydrogenphosphate [3]	19098-16-9 [3]	242-818-2 [3]
	Hydroxylamine 4-methylbenzenesulfonate [4]	53933-48-5 [4]	258-872-5 [4]
1510	(3-Chloro-2-hydroxypropyl) trimethylammonium chloride	3327-22-8	222-048-3
1511	Biphenyl-3,3',4,4'-tetrayltetraamine; diaminobenzidine	91-95-2	202-110-6

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

1512	Piperazine hydrochloride [1]	6094-40-2 [1]	228-042-7 [1]
	Piperazine dihydrochloride [2]	142-64-3 [2]	205-551-2 [2]
	Piperazine phosphate [3]	1951-97-9 [3]	217-775-8 [3]
1513	3-(Piperazin-1-yl)-benzo[d]isothiazole hydrochloride	87691-88-1	421-310-6
1514	2-Ethylphenylhydrazine hydrochloride	19398-06-2	421-460-2
1515	(2-Chloroethyl)(3-hydroxypropyl)ammonium chloride	40722-80-3	429-740-6
1516	4-[(3-Chlorophenyl)(1 <i>H</i> -imidazol-1-yl)methyl]-1,2-benzenediamine dihydrochloride	159939-85-2	425-030-5
1517	Chloro- <i>N,N</i> -dimethylformiminium chloride	3724-43-4	425-970-6
1518	7-Methoxy-6-(3-morpholin-4-yl-propoxy)-3 <i>H</i> -quinazolin-4-one	199327-61-2	429-400-7
1519	Reaction products of diisopropanolamine with formaldehyde (1:4)	220444-73-5	432-440-8
1520	3-Chloro-4-(3-fluorobenzyloxy)aniline	202197-26-0	445-590-4
1521	Ethidium bromide; 3,8-diamino-1-ethyl-6-phenylphenantridinium bromide	1239-45-8	214-984-6
1522	(<i>R,S</i>)-2-Amino-3,3-dimethylbutane amide	144177-62-8	447-860-7
1523	3-Amino-9-ethyl carbazole; 9-	132-32-1	205-057-7

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

	ethylcarbazol-3-ylamine		
1524	(6 <i>R</i> - <i>trans</i>)-1-((7-Ammonio-2-carboxylato-8-oxo-5-thia-1-azabicyclo-[4.2.0]oct-2-en-3-yl)methyl)pyridinium iodide	100988-63-4	423-260-0
1525	Forchlorfenuron (ISO); 1-(2-chloro-4-pyridyl)-3-phenylurea	68157-60-8	614-346-0
1526	Tetrahydro-1,3-dimethyl-1 <i>H</i> -pyrimidin-2-one; dimethyl propyleneurea	7226-23-5	230-625-6
1527	Quinoline	91-22-5	202-051-6
1528	Ketoconazole; 1-[4-[4-[[[(2 <i>SR</i> ,4 <i>RS</i>)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone	65277-42-1	265-667-4
1529	Metconazole (ISO); (1 <i>RS</i> ,5 <i>RS</i> ;1 <i>RS</i> ,5 <i>SR</i>)-5-(4-chlorobenzyl)-2,2-dimethyl-1-(1 <i>H</i> -1,2,4-triazol-1-ylmethyl)cyclopentanol	125116-23-6	603-031-3
1530	Potassium 1-methyl-3-morpholinocarbonyl-4-[3-(1-methyl-3-morpholinocarbonyl-5-oxo-2-pyrazolin-4-ylidene)-1-propenyl]pyrazole-5-olate	183196-57-8	418-260-2

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

1531	<i>N,N',N'</i> -Tris(2-methyl-2,3-epoxypropyl)-perhydro-2,4,6-oxo-1,3,5-triazine	26157-73-3	435-010-8
1532	Trimethylpropane tri(3-aziridinylpropanoate); (TAZ)	52234-82-9	257-765-0
1533	4,4'-Methylenediphenyl diisocyanate; diphenylmethane-4,4'-diisocyanate [1]	101-68-8 [1]	202-966-0 [1]
	2,2'-Methylenediphenyl diisocyanate; diphenylmethane-2,2'-diisocyanate [2]	2536-05-2 [2]	219-799-4 [2]
	<i>o</i> -(<i>p</i> -Isocyanatobenzyl)phenyl isocyanate; diphenylmethane-2,4'-diisocyanate [3]	5873-54-1 [3]	227-534-9 [3]
	Methylenediphenyl diisocyanate [4]	26447-40-5 [4]	247-714-0 [4]
1534	Cinidon ethyl (ISO); ethyl (<i>Z</i>)-2-chloro-3-[2-chloro-5-(cyclohex-1-ene-1,2-dicarboximido)phenyl]acrylate	142891-20-1	604-318-6
1535	<i>N</i> -[6,9-Dihydro-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-6-oxo-1 <i>H</i> -purin-2-yl]acetamide	84245-12-5	424-550-1
1536	Dimoxystrobin (ISO); (<i>E</i>)-2-(methoxyimino)- <i>N</i> -methyl-2-[α -(2,5-xylyloxy)- <i>o</i> -tolyl]acetamide	149961-52-4	604-712-8
1537	<i>N,N</i> -(Dimethylamino)thioacetamide hydrochloride	27366-72-9	435-470-1

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

1538	<p>Reaction mass of: 2,2'-[(3,3'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-(2,4-dimethylphenyl)]-3-oxo-butanamide; 2-[[[3,3'-dichloro-4'-[[1[[[(2,4-dimethylphenyl)amino]carbonyl]-2-oxopropyl]azo][1,1'-biphenyl]-4-yl]azo]-N-(2-methylphenyl)-3-oxo-butanamide; 2-[[[3,3'-dichloro-4'-[[1[[[(2,4-dimethylphenyl)amino]carbonyl]-2-oxopropyl]azo][1,1'-biphenyl]-4-yl]azo]-N-(2-carboxylphenyl)-3-oxo-butanamide</p>		434-330-5
1539	<p>Petroleum, coal, tar and natural gas and their derivatives generated using distillation and/or other processing methods if they contain $\geq 0,1$ % w/w benzene</p>	<p>85536-20-5 85536-19-2 90641-12-6 90989-38-1 91995-20-9 92062-36-7 91995-61-8 101316-63-6 93821-38-6 90641-02-4 101316-62-5 90641-03-5 65996-79-4 101794-90-5 90640-87-2 84650-03-3 65996-82-9 90641-01-3 65996-87-4 90640-99-6 68391-11-7 92062-33-4 91082-52-9 68937-63-3 92062-28-7 92062-27-6 91082-53-0 91995-31-2</p>	<p>287-502-5 287-500-4 292-636-2 292-694-9 295-281-1 295-551-9 295-323-9 309-868-8 298-725-2 292-625-2 309-867-2 292-626-8 266-013-0 309-971-8 292-609-5 283-483-2 266-016-7 292-624-7 266-021-4 292-622-6 269-929-9 295-548-2 293-766-2 273-077-3 295-543-5 295-541-4 293-767-8 295-292-1</p>

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

91995-35-6	295-295-8
91995-66-3	295-329-1
122070-79-5	310-170-0
122070-80-8	310-171-6
65996-78-3	266-012-5
94114-52-0	302-688-0
94114-53-1	302-689-6
94114-54-2	302-690-1
94114-56-4	302-692-2
94114-57-5	302-693-8
90641-11-5	292-635-7
8006-61-9	232-349-1
8030-30-6	232-443-2
8032-32-4	232-453-7
64741-41-9	265-041-0
64741-42-0	265-042-6
64741-46-4	265-046-8
64742-89-8	265-192-2
68410-05-9	270-077-5
68514-15-8	271-025-4
68606-11-1	271-727-0
68783-12-0	272-186-3
68921-08-4	272-931-2
101631-20-3	309-945-6
64741-64-6	265-066-7
64741-65-7	265-067-2
64741-66-8	265-068-8
64741-70-4	265-073-5
64741-84-0	265-086-6
64741-92-0	265-095-5
68410-71-9	270-088-5
68425-35-4	270-349-3
68527-27-5	271-267-0
91995-53-8	295-315-5
92045-49-3	295-430-0
92045-55-1	295-436-3
92045-58-4	295-440-5
92045-64-2	295-446-8
101316-67-0	309-871-4
64741-54-4	265-055-7
64741-55-5	265-056-2
68476-46-0	270-686-6
68783-09-5	272-185-8
91995-50-5	295-311-3
92045-50-6	295-431-6
92045-59-5	295-441-0
92128-94-4	295-794-0
101794-97-2	309-974-4
101896-28-0	309-987-5
64741-63-5	265-065-1
64741-68-0	265-070-9
68475-79-6	270-660-4
68476-47-1	270-687-1

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

68478-15-9	270-794-3
68513-03-1	270-993-5
68513-63-3	271-008-1
68514-79-4	271-058-4
68919-37-9	272-895-8
68955-35-1	273-271-8
85116-58-1	285-509-8
91995-18-5	295-279-0
93571-75-6	297-401-8
93572-29-3	297-458-9
93572-35-1	297-465-7
93572-36-2	297-466-2
64741-74-8	265-075-6
64741-83-9	265-085-0
67891-79-6	267-563-4
67891-80-9	267-565-5
68425-29-6	270-344-6
68475-70-7	270-658-3
68603-00-9	271-631-9
68603-01-0	271-632-4
68603-03-2	271-634-5
68955-29-3	273-266-0
92045-65-3	295-447-3
64742-48-9	265-150-3
64742-49-0	265-151-9
64742-73-0	265-178-6
68410-96-8	270-092-7
68410-97-9	270-093-2
68410-98-0	270-094-8
68512-78-7	270-988-8
85116-60-5	285-511-9
85116-61-6	285-512-4
92045-51-7	295-432-1
92045-52-8	295-433-7
92045-57-3	295-438-4
92045-61-9	295-443-1
92062-15-2	295-529-9
93165-55-0	296-942-7
93763-33-8	297-852-0
93763-34-9	297-853-6
64741-47-5	265-047-3
64741-48-6	265-048-9
64741-69-1	265-071-4
64741-78-2	265-079-8
64741-87-3	265-089-2
64742-15-0	265-115-2
64742-22-9	265-122-0
64742-23-0	265-123-6
64742-66-1	265-170-2
64742-83-2	265-187-5
64742-95-6	265-199-0
68131-49-7	268-618-5
68477-34-9	270-725-7

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

		68477-50-9	270-735-1
		68477-53-2	270-736-7
		68477-55-4	270-738-8
		68477-61-2	270-741-4
		68477-89-4	270-771-8
		68478-12-6	270-791-7
		68478-16-0	270-795-9
		68513-02-0	270-991-4
		68516-20-1	271-138-9
		68527-21-9	271-262-3
		68527-22-0	271-263-9
		68527-23-1	271-264-4
		68527-26-4	271-266-5
		68603-08-7	271-635-0
		68606-10-0	271-726-5
		68783-66-4	272-206-0
		68919-39-1	272-896-3
		68921-09-5	272-932-8
		85116-59-2	285-510-3
		86290-81-5	289-220-8
		90989-42-7	292-698-0
		91995-38-9	295-298-4
		91995-41-4	295-302-4
		91995-68-5	295-331-2
		92045-53-9	295-434-2
		92045-60-8	295-442-6
		92045-62-0	295-444-7
		92045-63-1	295-445-2
		92201-97-3	296-028-8
		93165-19-6	296-903-4
		94114-03-1	302-639-3
		95009-23-7	305-750-5
		97926-43-7	308-261-5
		98219-46-6	308-713-1
		98219-47-7	308-714-7
		101316-56-7	309-862-5
		101316-66-9	309-870-9
		101316-76-1	309-879-8
		101795-01-1	309-976-5
		102110-14-5	310-012-0
		68476-50-6	270-690-8
		68476-55-1	270-695-5
		90989-39-2	292-695-4
1540	Petroleum, coal, tar and natural gas and their derivatives generated using distillation and/or other processing methods if they contain \geq		

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

	0,005 % w/w benzo[a]pyrene		
		90640-85-0 92061-93-3 90640-84-9 61789-28-4 70321-79-8 122384-77-4 70321-80-1	292-606-9 295-506-3 292-605-3 263-047-8 274-565-9 310-189-4 274-566-4
1541	Petroleum, coal, tar and natural gas and their derivatives generated using distillation and/or other processing methods if they contain $\geq 0,1$ % w/w benzene or if they contain $\geq 0,005$ % w/w benzo[a]pyrene		
		85029-51-2 84650-04-4 84989-09-3 91995-49-2 121620-47-1 121620-48-2 90640-90-7 90641-04-6 101896-27-9 101794-91-6 91995-48-1 90641-05-7 84989-12-8 121620-46-0 90640-81-6 90640-82-7 92061-92-2 91995-15-2 91995-16-3 91995-17-4 101316-87-4 122384-78-5 84988-93-2 90640-88-3 65996-83-0 90640-89-4 90641-06-8 65996-85-2 101316-86-3 92062-22-1	285-076-5 283-484-8 284-898-1 295-310-8 310-166-9 310-167-4 292-612-1 292-627-3 309-985-4 309-972-3 295-309-2 292-628-9 284-901-6 310-165-3 292-603-2 292-604-8 295-505-8 295-275-9 295-276-4 295-278-5 309-889-2 310-191-5 284-881-9 292-610-0 266-017-2 292-611-6 292-629-4 266-019-3 309-888-7 295-536-7

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

		96690-55-0 84989-04-8 84989-05-9 84989-06-0 84989-03-7 84989-07-1 68477-23-6 68555-24-8 91079-47-9 92062-26-5 94114-29-1 90641-00-2 68513-87-1 70321-67-4 92062-29-8 100801-63-6 100801-65-8 100801-66-9 73665-18-6 68815-21-4 65996-86-3 65996-84-1	306-251-5 284-892-9 284-893-4 284-895-5 284-891-3 284-896-0 270-713-1 271-418-0 293-435-2 295-540-9 302-662-9 292-623-1 271-020-7 274-560-1 295-544-0 309-745-9 309-748-5 309-749-0 277-567-8 272-361-4 266-020-9 266-018-8
1542	Petroleum, coal, tar and natural gas and their derivatives generated using distillation and/or other processing methods if they contain $\geq 0,1$ % w/w 1,3-butadiene		
		68607-11-4 68783-06-2 68814-67-5 68814-90-4 68911-58-0 68911-59-1 68919-01-7 68919-02-8 68919-03-9 68919-04-0 68919-07-3 68919-08-4 68919-11-9 68919-12-0 68952-79-4 68952-80-7 68955-33-9 68989-88-8 92045-15-3 92045-16-4 92045-17-5	271-750-6 272-182-1 272-338-9 272-343-6 272-775-5 272-776-0 272-873-8 272-874-3 272-875-9 272-876-4 272-880-6 272-881-1 272-884-8 272-885-3 273-173-5 273-174-0 273-269-7 273-563-5 295-397-2 295-398-8 295-399-3

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

		92045-18-6	295-400-7
		92045-19-7	295-401-2
		92045-20-0	295-402-8
		68131-75-9	268-629-5
		68307-98-2	269-617-2
		68307-99-3	269-618-8
		68308-00-9	269-619-3
		68308-01-0	269-620-9
		68308-10-1	269-630-3
		68308-03-2	269-623-5
		68308-04-3	269-624-0
		68308-05-4	269-625-6
		68308-06-5	269-626-1
		68308-07-6	269-627-7
		68308-09-8	269-629-8
		68308-11-2	269-631-9
		68308-12-3	269-632-4
		68409-99-4	270-071-2
		68475-57-0	270-651-5
		68475-58-1	270-652-0
		68475-59-2	270-653-6
		68475-60-5	270-654-1
		68476-26-6	270-667-2
		68476-29-9	270-670-9
		68476-40-4	270-681-9
		68476-42-6	270-682-4
		68476-49-3	270-689-2
		68476-85-7	270-704-2
		68476-86-8	270-705-8
		68477-33-8	270-724-1
		68477-35-0	270-726-2
		68477-69-0	270-750-3
		68477-70-3	270-751-9
		68477-71-4	270-752-4
		68477-72-5	270-754-5
		68308-08-7	269-628-2
1543	Tris[2-chloro-1-(chloromethyl)ethyl] phosphate	13674-87-8	237-159-2
1544	Indium phosphide	22398-80-7	244-959-5
1545	Trixylyl phosphate	25155-23-1	246-677-8
1546	Hexabromocyclododecane [1]	25637-99-4 [1]	247-148-4 [1]
	1,2,5,6,9,10-Hexabromocyclododecane [2]	3194-55-6 [2]	221-695-9 [2]
1547	Tetrahydrofuran	109-99-9	203-726-8
1548	Abamectin (combination of	71751-41-2 [1]	615-339-5 [1]

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

	avermectin B1a and avermectin B1b) (ISO) [1]		
	Avermectin B1a [2]	65195-55-3 [2]	265-610-3 [2]
1549	4- <i>tert</i> -Butylbenzoic acid	98-73-7	202-696-3
1550	Leucomalachite green; <i>N,N,N',N'</i> -tetramethyl-4,4'-benzylidenedianiline	129-73-7	204-961-9
1551	Fuberidazole (ISO); 2-(2-furyl)-1 <i>H</i> -benzimidazole	3878-19-1	223-404-0
1552	Metazachlor (ISO); 2-chloro- <i>N</i> -(2,6-dimethylphenyl)- <i>N</i> -(1 <i>H</i> -pyrazol-1-ylmethyl)acetamide	67129-08-2	266-583-0
1553	Di- <i>tert</i> -butyl peroxide	110-05-4	203-733-6
1554	Trichloromethylstannane	993-16-8	213-608-8
1555	2-Ethylhexyl 10-ethyl-4-[[2-[(2-ethylhexyl)oxy]-2-oxoethyl]thio]-4-methyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate	57583-34-3	260-828-5
1556	2-Ethylhexyl 10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate	15571-58-1	239-622-4
1557	Sulcotrione (ISO); 2-[2-chloro-4-(methylsulfonyl)benzoyl]cyclohexane-1,3-dione	99105-77-8	619-394-6
1558	Bifenthrin (ISO); (2-methylbiphenyl-3-yl)methyl <i>rel</i> -(1 <i>R</i> ,3 <i>R</i>)-3-[(1 <i>Z</i>)-2-chloro-3,3,3-trifluoroprop-1-	82657-04-3	617-373-6

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

	en-1-yl]-2,2-dimethylcyclopropanecarboxylate		
1559	Dihexyl phthalate	84-75-3	201-559-5
1560	Ammonium pentadecafluorooctanoate	3825-26-1	223-320-4
1561	Perfluorooctanoic acid	335-67-1	206-397-9
1562	N-Ethyl-2-pyrrolidone; 1-ethylpyrrolidin-2-one	2687-91-4	220-250-6
1563	Proquinazid (ISO); 6-iodo-2-propoxy-3-propylquinazolin-4(3H)-one	189278-12-4	606-168-7
1564	Gallium arsenide	1303-00-0	215-114-8
1565	Vinyl acetate	108-05-4	203-545-4
1566	Aclonifen (ISO); 2-chloro-6-nitro-3-phenoxyaniline	74070-46-5	277-704-1
1567	2-Ethylhexyl 10-ethyl-4,4-dimethyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate	57583-35-4	260-829-0
1568	Dimethyltin dichloride	753-73-1	212-039-2
1569	4-Vinylcyclohexene	100-40-3	202-848-9
1570	Tralkoxydim (ISO); 2-(N-ethoxypropanimidoyl)-3-hydroxy-5-mesitylcyclohex-2-en-1-one	87820-88-0	618-075-9
1571	Cycloxydim (ISO); 2-(N-ethoxybutanimidoyl)-3-hydroxy-5-(tetrahydro-2H-thiopyran-3-yl)cyclohex-2-en-1-one	101205-02-1	405-230-9

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

1572	Fluazinam (ISO); 3-chloro- <i>N</i> - [3-chloro-2,6- dinitro-4- (trifluoromethyl)phenyl]-5- (trifluoromethyl)pyridin-2- amine	79622-59-6	616-712-5
1573	Penconazole (ISO); 1-[2-(2,4- dichlorophenyl)pentyl]-1 <i>H</i> -1,2,4- triazole	66246-88-6	266-275-6
1574	Fenoxycarb (ISO); ethyl [2-(4- phenoxyphenoxy)ethyl]carbamate	72490-01-8	276-696-7
1575	Styrene	100-42-5	202-851-5
1576	Tetrahydro-2- furylmethanol; tetrahydrofurfuryl alcohol	97-99-4	202-625-6
1577	Formaldehyde	50-00-0	200-001-8
1578	Paraformaldehyde	30525-89-4	608-494-5
1579	Methanediol; methylene glycol	463-57-0	207-339-5
1580	Cymoxanil (ISO); 2-cyano- <i>N</i> - [(ethylamino)carbonyl]-2- (methoxyimino)acetamide	57966-95-7	261-043-0
1581	Tributyltin compounds	—	—
1582	Tembotrione (ISO); 2-{2- chloro-4- (methylsulfonyl)-3- [(2,2,2- trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3- dione	335104-84-2	608-879-8
1583	1,2- Benzenedicarboxylic acid, dihexyl ester, branched and linear	68515-50-4	271-093-5
1584	Spirotetramat (ISO); (5 <i>s</i> ,8 <i>s</i>)-3-(2,5- dimethylphenyl)-8- methoxy-2-oxo-1- azaspiro[4,5]dec-3-	203313-25-1	606-523-6

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

	en-4-yl ethyl carbonate		
1585	Dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate	31717-87-0	250-778-2
1586	Triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate	126535-15-7	603-146-9
1587	Imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole	35554-44-0	252-615-0
1588	Dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine	1593-77-7	216-474-9
1589	Imidazole	288-32-4	206-019-2
1590	Lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione	2164-08-1	218-499-0
1591	Metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide	139528-85-1	604-145-6
1592	2-Methyl-1-(4-methylthiophenyl)-2-morpholino-propan-1-one	71868-10-5	400-600-6
1593	2,3-Epoxypropyl methacrylate; glycidyl methacrylate	106-91-2	203-441-9
1594	Spiroxamine (ISO); 8-tert-butyl-1,4-	118134-30-8	601-505-4

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

	dioxaspirol[4.5]decan-2-ylmethyl(ethyl)(propyl)amine		
1595	Cyanamide; carbanonitril	420-04-2	206-992-3
1596	Cyproconazole (ISO); (2 <i>RS</i> ,3 <i>RS</i> ;2 <i>RS</i> ,3 <i>SR</i>)-2-(4-chlorophenyl)-3-cyclopropyl-1-(1 <i>H</i> -1,2,4-triazol-1-yl)butan-2-ol	94361-06-5	619-020-1
1597	Silver zinc zeolite	130328-20-0	603-404-0
1598	Cadmium carbonate	513-78-0	208-168-9
1599	Cadmium hydroxide; cadmium dihydroxide	21041-95-2	244-168-5
1600	Cadmium nitrate; cadmium dinitrate	10325-94-7	233-710-6
1601	Dibutyltin dilaurate; dibutyl[bis(dodecanoyloxy)]stannane	77-58-7	201-039-8
1602	Clorofene; chlorophene; 2-benzyl-4-chlorophenol	120-32-1	204-385-8
1603	Anthraquinone	84-65-1	201-549-0
1604	Nonadecafluorodecanoic acid [1]	335-76-2 [1]	206-400-3[1]
	Ammonium nonadecafluorodecanoate [2]	3108-42-7 [2]	221-470-5 [2] [3]
	Sodium nonadecafluorodecanoate [3]	3830-45-3 [3]	
1605	<i>N,N'</i> -Methylenedimorpholine; <i>N,N'</i> -methylenebismorpholine; [formaldehyde released from <i>N,N'</i> -	5625-90-1	227-062-3

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

	Methylenebismorpholine]; [MBM] if the maximum theoretical concentration of releasable formaldehyde, irrespective of the source, in the mixture as placed on the market is \geq 0,1 % w/w		
1606	Reaction products of paraformaldehyde with 2-hydroxypropylamine (3:2); [formaldehyde released from 3,3'-methylenebis[5-methyloxazolidine]; [formaldehyde released from oxazolidin]; [MBO] if the maximum theoretical concentration of releasable formaldehyde, irrespective of the source, in the mixture as placed on the market is \geq 0,1 % w/w	—	—
1607	Reaction products of paraformaldehyde with 2-hydroxypropylamine (1:1); [formaldehyde released from α,α,α -trimethyl-1,3,5-triazine-1,3,5(2H,4H,6H)-triethanol]; [HPT] if the maximum theoretical concentration of releasable	—	—

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

	formaldehyde, irrespective of the source, in the mixture as placed on the market is \geq 0,1 % w/w		
1608	Methylhydrazine	60-34-4	200-471-4
1609	Triadimenol (ISO); (1 <i>RS</i> ,2 <i>RS</i> ;1 <i>RS</i> ,2 <i>SR</i>)-1-(4-chlorophenoxy)-3,3-dimethyl-1-(1 <i>H</i> -1,2,4-triazol-1-yl)butan-2-ol; <i>tert</i> -butyl- β -(4-chlorophenoxy)-1 <i>H</i> -1,2,4-triazole-1-ethanol	55219-65-3	259-537-6
1610	Thiacloprid (ISO); (Z)-3-(6-chloro-3-pyridylmethyl)-1,3-thiazolidin-2-ylidenecyanamide; {(2Z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide	111988-49-9	601-147-9
1611	Carbetamide (ISO); (R)-1-(ethylcarbamoyl)ethyl-carbanilate; (2R)-1-(ethylamino)-1-oxopropan-2-ylphenylcarbamate	16118-49-3	240-286-6'

(b) entry 395 is replaced by the following:

Reference number	Substance identification		
	Chemical name/INN	CAS number	EC number
'395	Hydroxy-8-quinoline and its sulphate	148-24-2 134-31-6	205-711-1 205-137-1'

(2) Annex III is amended as follows:

(a) entries 1a, 1b, 7, 13 and 51 are deleted;

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

(b) entry 12 is replaced by the following:

Reference number	Substance identification				Restrictions			Wording of conditions of use and warnings
	Chemical name/INN	Name of Common Ingredients Glossary	CAS number	EC number	Product type, body parts	Maximum concentration in ready for use preparation	Other	
a	b	c	d	e	f	g	h	i
12	Hydrogen peroxide and other compounds or mixtures that release hydrogen peroxide, including carbamide peroxide and zinc peroxide, with the exception of the following substances in Annex II: —	Hydrogen peroxide	7722-84-1	231-765-0	(a)	Hair products	12 % of H ₂ O ₂ (40 volumes) present or released	(a) (f) Wear suitable gloves (a) (b) (c) (e) Contains hydrogen peroxide Avoid contact with eyes Rinse immediately if product comes into contact with them.
					(b)	Shin products	4 % of H ₂ O ₂ , present or released	
					(c)	Nail hardening products	2 % of H ₂ O ₂ , present or released	
					(d)	Oral products, including mouth rinse, tooth paste and tooth whitening or	≤ 0,1 % of H ₂ O ₂ , present or released	

a Directive 2005/36/EC of the European Parliament and of the Council of 7 September 2005 on the recognition of professional qualifications (OJ L 255, 30.9.2005, p. 22).;

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

					bleaching products	
				(e)	<p>(e) Both whitening or bleaching products</p> <p>(e) 0,1 % ≤ 6 % of H₂O₂, present or released</p>	<p>(e) Concentration of H₂O₂ present or released and indicated in percentage.</p> <p>(e) to be used by dental practitioners. Each cycle of use, the European Parliament has only done by dental practitioners or under their direct supervision if an equivalent safety is ensured. Afterwards provided to the consumer</p>

a Directive 2005/36/EC of the European Parliament and of the Council of 7 September 2005 on the recognition of professional qualifications (OJ L 255, 30.9.2005, p. 22).;

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

						to the consumer to complete the cycle of use. Not to be used on a person under 18 years of age.	to complete the cycle of use.
				(f)	Products intended for eyelashes	(f) % of H ₂ O ₂ , present or released	For professional use only To be printed on the label: For professional use only. Avoid contact with eyes. Rinse eyes immediately if product comes into contact with them. Contains hydrogen peroxide

a Directive 2005/36/EC of the European Parliament and of the Council of 7 September 2005 on the recognition of professional qualifications (OJ L 255, 30.9.2005, p. 22).;

(c) the following entries are added:

Ref No.	Substance identification	Restrictions	Wording of conditions of use and warnings

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

	Chemical name/INN	Name of Common Ingredients Glossary	CAS number	EC number	Product type, body parts	Maximum concentration in ready for use preparation	Other	
a	b	c	d	e	f	g	h	i
'311	Diphenyl(trimethylphosphine)oxide	(Di-4-methylphenyl)phosphine oxide	15980-6028	202-627-7	Artificial nail systems	5,0 %	Professional use	For professional use only Avoid skin contact Read directions for use carefully
312	2-Furaldehyde	Furfural	98-01-1	202-627-7		0,001 %'		

(3) Annex V is amended as follows:

(a) point 2 of the preamble is replaced by the following:

2. All finished products containing substances in this Annex and which release formaldehyde must be labelled with the warning 'contains formaldehyde' where the concentration of formaldehyde in the finished product exceeds 0,05 %

(b) entries 5, 31, 40 and 41 are deleted;

(c) entry 28 is replaced by the following:

Reference number	Substance Identification				Conditions			Wording of conditions of use and warnings
	Chemical name/INN	Name of Common Ingredients Glossary	CAS number	EC number	Product type, Body parts	Maximum concentration in ready for use preparation	Other	
a	b	c	d	e	f	g	h	i
'28	Polyhexamethylene biguanide hydrochloride	Polyhexamethylene biguanide	32289-5860 27083-2768 28757-47-3, 133029-32-0	202-627-9 202-627-7		0,1 %	Not to be used in applications	

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

							that may lead to exposure of the end- user's lungs by inhalation'	
--	--	--	--	--	--	--	----------------------------------------------------------------------------------------------	--

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831. (See end of Document for details)

- (1) [OJ L 342, 22.12.2009, p. 59.](#)
- (2) Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 ([OJ L 353, 31.12.2008, p. 1](#)).
- (3) Commission Regulation (EU) 2017/776 of 4 May 2017 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures ([OJ L 116, 5.5.2017, p. 1](#)).
- (4) Commission Regulation (EC) No 790/2009 of 10 August 2009 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures ([OJ L 235, 5.9.2009, p. 1](#)).
- (5) SCCS/1344/10, http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_077.pdf.
- (6) SCCS/1360/10, http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_053.pdf.
- (7) SCCS/1408/11, https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_118.pdf.
- (8) SCCS/1547/15, https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_170.pdf.
- (9) Commission Regulation (EU) No 605/2014 of 5 June 2014 amending, for the purposes of introducing hazard and precautionary statements in the Croatian language and its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures ([OJ L 167, 6.6.2014, p. 36](#)).
- (10) SCCS/1538/14, https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_164.pdf.
- (11) SCCS/1345/10, https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_031.pdf.
- (12) Commission Regulation (EU) No 618/2012 of 10 July 2012 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures ([OJ L 179, 11.7.2012, p. 3](#)).
- (13) SCCS/1528/14, http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_149.pdf.
- (14) SCCS/1461/12, https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_083.pdf.
- (15) Commission Regulation (EU) No 944/2013 of 2 October 2013 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures ([OJ L 261, 3.10.2013, p. 5](#)).
- (16) SCCS/1535/14, https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_157.pdf.
- (17) SCCS/1581/16, https://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_204.pdf.
- (18) SCCS/1249/09, https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_027.pdf.
- (19) SCCS/1523/13, https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_146.pdf.
- (20) SCCS/1483/12, https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_097.pdf.

Changes to legislation:

There are currently no known outstanding effects for the Commission Regulation (EU) 2019/831.